• 1. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 2. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 3. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 4. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 5. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines N-benzylpiperidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Benzylpiperidines N-benzylpiperidines

Professional Introduction to Compound with CAS No. 59009-70-0 and Product Name: 3,7-Dibenzyl-3,7-diazabicyclo3.3.1nonan-9-one

The compound with the CAS number 59009-70-0 and the product name 3,7-Dibenzyl-3,7-diazabicyclo3.3.1nonan-9-one represents a significant advancement in the field of organic chemistry and pharmaceutical research. This bicyclic structure, characterized by its unique fused ring system and nitrogen-containing heterocycles, has garnered considerable attention due to its potential applications in medicinal chemistry and drug discovery.

At the core of this compound's appeal lies its intricate molecular architecture. The presence of two benzyl groups at the 3 and 7 positions enhances its lipophilicity, making it a promising candidate for membrane-permeable drugs. Additionally, the diazabicyclo[3.3.1]nonane core introduces rigidity to the molecule, which can be advantageous in stabilizing protein-ligand interactions. Such structural features are particularly relevant in the development of small-molecule inhibitors targeting complex biological pathways.

Recent research has highlighted the utility of 3,7-Dibenzyl-3,7-diazabicyclo3.3.1nonan-9-one as a scaffold for designing novel therapeutic agents. Its bicyclic nature allows for conformational flexibility while maintaining structural integrity, which is crucial for effective binding to biological targets. Studies have demonstrated its potential in modulating enzyme activity and receptor interactions, particularly in the context of inflammatory and neurodegenerative diseases.

In the realm of drug discovery, the synthesis of derivatives of 3,7-Dibenzyl-3,7-diazabicyclo3.3.1nonan-9-one has been extensively explored. Researchers have leveraged its chemical versatility to introduce various functional groups, thereby tailoring its pharmacological properties for specific therapeutic applications. For instance, modifications at the benzyl positions have been shown to influence metabolic stability and binding affinity, underscoring the importance of structure-activity relationships (SAR) in optimizing drug candidates.

The compound's unique pharmacophore has also attracted interest for its potential role in addressing unmet medical needs. By serving as a versatile building block, 3,7-Dibenzyl-3,7-diazabicyclo3.3.1nonan-9-one enables the rapid design and synthesis of libraries of compounds for high-throughput screening (HTS). This approach has accelerated the identification of lead molecules with promising preclinical profiles, streamlining the drug development pipeline.

Advances in computational chemistry have further enhanced our understanding of 59009-70-0's interactions with biological targets. Molecular modeling studies have revealed insights into its binding mode at various receptors and enzymes, providing a rational basis for designing next-generation analogs with improved efficacy and selectivity. These computational tools are indispensable in modern drug discovery, allowing researchers to predict and optimize molecular properties before experimental validation.

The synthetic methodologies employed in producing 59009-70-0 are another area of active investigation. Transition-metal-catalyzed reactions have emerged as powerful tools for constructing complex cyclic frameworks efficiently. Techniques such as palladium-catalyzed cross-coupling reactions and copper-mediated cyclizations have been instrumental in accessing derivatives of 3,7-Dibenzyl-3,7-diazabicyclo3.3.1nonan-9-one with high yields and purity.

Future directions in research may focus on exploring the compound's role in interdisciplinary fields such as materials science and nanotechnology. Its rigid yet flexible structure could make it a valuable component in designing functional materials or as a precursor for novel polymers with tailored properties. Such applications would expand beyond traditional pharmaceuticals into emerging areas where molecular architecture plays a critical role.

In conclusion,59009-70-0 and its derivative 3,7-Dibenzyl-3,7-diazabicyclo[3.3.1]nonan-9-one represent a fascinating example of how structural innovation can drive advancements in medicine and science. The ongoing exploration of its chemical space promises to yield novel therapeutics targeting diverse diseases while also opening new avenues for industrial applications.

• 34737-89-8(1-benzyl-3-methylpiperidin-4-one)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)